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| INTRODUC TI ON
Multiple myeloma (MM) is a hematological malignancy characterized by the accumulation of plasma cells in the bone marrow. 1, 2 It is a rare disease accounting for 1% of new cases of cancer and 10% of hematological cancers.
1 Following the introduction of autologous stem cell transplantation (SCT) in the early 1980s, there were few developments in the treatment of MM for many years.
Almost 2 decades later, the proteasome was identified as a novel therapeutic target for cancer treatment and proteasome inhibition proved to be an effective strategy in MM. 3, 4 Bortezomib-the first-in-class proteasome inhibitor, with boronic acid as its ac- 6, 7 Shortly afterward, the immunomodulatory agents, lenalidomide and thalidomide, were also approved in Europe and the United
States for use in patients with MM. [8] [9] [10] Over the last 12 years, bortezomib has become a mainstay of MM therapy. It is widely used as a single agent or in combination with conventional chemotherapy drugs (eg, cyclophosphamide and melphalan), immunomodulatory agents and steroids, both for its initial indication in patients 
R E V I E W A R T I C L E

The start of a new wave: Developments in proteasome inhibition in multiple myeloma
with relapsed MM and as the standard of care first-line treatment option. 6, 11 Bortezomib use, however, may be limited by primary and secondary resistance, 12 as well as by dose-limiting adverse events (AEs), particularly peripheral neuropathy. 13 Dose and schedule adjustments, and the development of a subcutaneous formulation, have reduced the incidence of peripheral neuropathy and helped to optimize the benefit-risk profile of bortezomib. [13] [14] [15] [16] Nevertheless, despite the progress made, there continues to be a need for fur-
ther development and refinement of proteasome inhibition as a therapeutic strategy. Exploration of alternative active moieties (eg, epoxyketones and lactones) has focused on optimized selective destruction of malignant cells, with preservation of healthy cells and limited toxicity. 6 This work culminated in a new wave of agents, the first of which-carfilzomib (Figure 1 ), an epoxyketone-based proteasome inhibitor-was approved by the FDA in 2012 17 and by the EMA in 2015. 18 Ixazomib, a second-generation boronic acid orally administered agent (Figure 1 ), was approved in the United States in late 2015 19 and recently received approval for use in Europe. 20 Other compounds, such as the intravenously administered agent marizomib and the orally administered agent oprozomib (Figure 1 ), are in early stages of clinical development. 21, 22 This review explores the evolving role of proteasome inhibition as a therapeutic strategy, with particular focus on the clinical features of bortezomib and carfilzomib. The ways in which their different molecular structures and actions at the proteasome level are related to their respective clinical efficacy and safety profiles are also discussed.
| THE CON S TITUTIVE PROTE A SOME AND THE IMMUNOPROTE A SOME
The ubiquitin-proteasome system is responsible for the degradation of intracellular proteins and the maintenance of cellular protein homeostasis. The 26S proteasome is a multisubunit protease complex, comprising a 20S catalytic core together with 1 or 2 19S regulatory subunits ( Figure 2 ). 23 Proteins are "tagged" for degradation by the proteasome through conjugation with ubiquitin.
Polyubiquitinated proteins are recognized and bound by the 19S regulatory cap of the proteasome, where they are deubiquitinated before being internalized to the 20S core to be degraded. 23 The 20S core is composed of 2 inner β-rings and 2 outer α-rings. In the constitutive proteasome, the β-rings each contain 3 proteolytic 
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Lactone active moiety sites named according to their chymotrypsin-like (β5), trypsin-like (β2), or caspase-like (β1) activity. [24] [25] [26] The chymotrypsin-like site is believed to be the key therapeutic target for proteasome inhibition 27 ; however, all 3 sites contribute to protein degradation.
Therefore, additional inhibition of the trypsin-like (β2-) or caspaselike (β1-) subunits may be required to achieve optimal inhibition of the proteasome. 25 Inhibition of the ubiquitin-proteasome pathway affects a number of components in cell signaling pathways, leading to cell cycle arrest, promotion of apoptosis, and disruption of the stress response. 23, 28, 29 Central to the use of proteasome inhibitors as targeted cancer treatments is the fact that malignant cells appear to be particularly susceptible to the effects of these agents. 29, 30 MM cells produce markedly large quantities of proteins (often referred to as M-protein), in the form of immunoglobulin chains, and are heavily dependent on proteasome-controlled signaling pathways for protein degradation. The accumulation of aggregated proteins that results from proteasome inhibition is disproportionately toxic to these cells compared with healthy cells. 31 It is also relevant to consider the immunoproteasome, which is a specialized proteasome featuring modified proteolytic β-subunits found mainly in lymphoid-derived cells. 32 Although there does appear to be overlap between the roles of the constitutive proteasome and the immunoproteasome, 32, 33 it has been postulated that immunoproteasome-specific inhibitors could preserve efficacy while reducing treatment-emergent toxicities, by sparing other tissues with little or no immunoproteasome expression. 32 However, Parlati et al found that specific inhibition of either the constitutive proteasome or the immunoproteasome alone was insufficient to promote an antitumorigenic effect; combined inhibition was required for cytotoxicity.
| AG ENTS WITH MECHANIS MS OF AC TI ON THAT COMPLEMENT PROTE A SOME INHIB ITION
Proteasome inhibitors have synergistic interactions with other drug classes. The altered proteolytic activity of the immunoproteasome results in the production of peptide substrates that are highly optimized for presentation on major histocompatibility complex (MHC) class I molecules. By reducing the surface expression of host protein fragments on MHC class I molecules, the action of proteasome inhibitors is thought to enhance natural killer cell-mediated cytotoxicity. 34 Given the potential for immunomodulatory drugs to stimulate natural killer cells, 35 this may be 1 explanation for the efficacy of combination therapy with these 2 classes of agent.
An alternative pathway for degrading misfolded proteins is via the aggresome, which is regulated independently from the proteasome. Ubiquitinated proteins form aggregates in the cytosol, which are then transported into lysosomes and degraded by proteolytic enzymes. 36 Histone deacetylase (HDAC) 6 is an enzyme that facilitates several steps of the aggresome pathway. Agents that inhibit this enzyme increase the quantity of cytotoxic aggregated proteins, 36 providing a basis for the synergism between HDAC6 inhibitors and proteasome inhibitors. 37 The HDAC inhibitor panobinostat has been shown to augment the antimyeloma activity of bortezomib in a phase 3 clinical trial.
38
A synergistic antimyeloma effect was also observed in vitro when bortezomib was combined with the alkylating agent melphalan, 39 possibly related to the effect of proteasome inhibition on the DNA damage response. 40, 41 The phase 3 VISTA trial demonstrated superior outcomes when bortezomib was added to melphalan and prednisolone compared with melphalan and prednisolone alone in patients with previously untreated MM. 42 
| PROTE A SOME INHIB ITOR S APPROVED IN EUROPE AND THE UNITED S TATE S
Currently, bortezomib, carfilzomib, and ixazomib are approved for the treatment of MM in Europe and the United States. 5, 7, [17] [18] [19] [20] Their different biological features are reflected in their respective clinical efficacy and safety profiles, providing an insight into the current value and future potential of this class of agents in cancer therapy. Thus, we focus on these 3 agents, but also include 
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Bortezomib Carfilzomib a brief discussion of emerging therapeutics in earlier stages of development.
| BORTE ZOMIB
Bortezomib was initially approved in the United States in 2003
for the treatment of relapsed and/or refractory MM (RRMM) and European approval followed shortly in 2004. 5, 43 Subsequently, the European indication has been extended to the first-line treatment setting. Bortezomib in combination with dexamethasone (with or without thalidomide) is approved for use as induction therapy for patients eligible for SCT and in combination with melphalan and prednisone for patients who are not eligible for SCT (Table 1) . [5] [6] [7] In the United States, bortezomib is licensed for use in newly diagnosed patients with MM (in combination with melphalan and prednisone) and in patients with relapsed MM (either as a single agent or in combination with dexamethasone). 
| Clinical data in patients with RRMM
Approval for bortezomib in the second-line setting was based on the pivotal APEX, MMY-3001, and MMVAR/IFM 2005-04 phase 3 studies (Table 2) . 44 RRMM. The median time to progression was significantly longer in the combination therapy group than in the monotherapy group (9.3 months vs 6.5 months; HR, 1.82; P = .000004), as was the 15-month survival rate (76% vs 65%; P = .03) and the duration of response (10.2 months vs 7.0 months; P = .0008). 45 The incidence of peripheral neuropathy was similar in both groups (35% vs 39%
for the combination and the monotherapy arms, respectively).
Combination therapy was associated with an increased incidence of grade 3 or 4 AEs (80% vs 64%), including thrombocytopenia as well as gastrointestinal and dermatological toxicities. 45 Common AEs (at any grade) included sensory neuropathy (53%), neutropenia (42%), and diarrhea (41%). P < .001). 49 These findings suggest that the combinations of daratumumab and other proteasome inhibitors, such as carfilzomib and ixazomib, could also provide survival benefits for patients with MM.
| Clinical data in patients with newly diagnosed MM
Approval for the use of bortezomib in the first-line treatment setting in patients not eligible for high-dose chemotherapy was based on results from the phase 3 VISTA study, which compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with MM who were ineligible for high-dose chemotherapy and SCT (Table 1) . 50 The addition of bortezomib to melphalan and prednisone was associated with a significant increase in median time to disease progression (the primary endpoint), which was 24.0 months in the bortezomib group compared with 16.6 months in the control group (HR for the bortezomib group, 0.48; P < .001). 50 After a median follow-up period of 60.1 months, the median OS was 56.4 months for patients in the bortezomib group and 43.1 months for those in the control group (HR, 0.70; P < .001). 42 However, the incidence of peripheral neuropathy (any grade) was considerably higher in patients receiving bortezomib than in those receiving melphalan and prednisone alone (44% vs 5%). 50 rates of 31-35% vs 11%-14% (P < .0001). 52, 53 As observed in the earlier bortezomib studies, however, the incidence of grade 3 or 4 peripheral neuropathy also increased (10%-14% vs 2%-5%).
Early-phase data suggest that the combination of bortezomib and lenalidomide may be beneficial for patients with newly diagnosed MM. In a phase 1/2 study, the estimated 18-month PFS and OS rates with bortezomib and lenalidomide were 75% and 97%, respectively, regardless of whether patients received SCT. The most common toxicity was sensory neuropathy, which was reported in 80% of patients, and 32% of patients had neuropathic pain. 54 The adjusted HR for disease progression or death, 0.65; P < .001). 56 The phase 3 Southwestern Oncology Group (SWOG) S0777 trial investigated bortezomib with lenalidomide and dexamethasone compared with lenalidomide and dexamethasone alone in patients with newly diagnosed MM for whom an immediate SCT was not planned.
Addition of bortezomib was associated with significantly longer median PFS and OS than lenalidomide and dexamethasone alone (PFS: 43 months vs 30 months, 1-sided P = .0018; OS: 75 months vs 64 months; 2-sided P = .025). 57 Bortezomib continues to be studied in numerous phase 3 studies, predominantly in patients with MM in the first-line setting.
The AE profile of bortezomib can, in part, be attributed to the way in which it binds to the proteasome (Figure 2 ). Bortezomib binds reversibly to its primary target-the β5-subunit of the 26S proteasome (β5i in the immunoproteasome). 29 The reversibility of this binding means that the drug must be given at doses high enough to maintain binding and therefore inhibition. However, bortezomib is associated with non-proteasome serine protease binding, which can lead to AEs. For example, evidence suggests that peripheral neuropathy is caused by inhibition of the HtrA2/Omi, a serine protease that is critical for neuronal cell survival. 58 Grade 3 or 4 peripheral neuropathy is seen in up to 28% of patients receiving intravenous biweekly bortezomib 15 The incidence of neuropathy can be reduced by, switching to a subcutaneous formulation, reducing the dose (1.3 mg to 1.0 mg), and adjusting the schedule (biweekly to onceweekly administration), but it remains a dose-limiting factor. 13, 16 .
| C ARFIL ZOMIB
The FDA approved carfilzomib for use in patients with MM in 2012, 17 and after more than a decade of bortezomib being the only protea- Carfilzomib is structurally and mechanistically distinct from bortezomib. 59 Unlike bortezomib, which binds reversibly through its boronic acid functional group, carfilzomib has an epoxyketone as its active moiety (Figure 1) . Consequently, carfilzomib binds irreversibly, 60 providing sustained proteasome inhibition. 61 Carfilzomib and bortezomib both bind to the β5-and β2-subunits of the constitutive proteasome and have similar 1-hour inhibitory concentrations (IC 50 ) for proteolytic activity at these sites (β5-subunit: 6 nmol/L and 7 nmol/L, respectively, and β2-subunit: 3600 nmol/L and 4200 nmol/L, respectively). 62 Carfilzomib, however, is more selective for the β5-subunit over the β1-subunit than bortezomib (IC 50 β1-subunit: 2400 nmol/L for carfilzomib and 74 nmol/L for bortezomib). 62 A similar pattern of selectivity is observed for carfilzomib binding to the immunoproteasome. 63 More pertinently, lower levels of off-target protease inhibition are observed with carfilzomib than with bortezomib, including activity at the HtrA2/Omi protease; this may explain the difference in incidence of peripheral neuropathy associated with the 2 proteasome inhibitors. 
| Clinical trials in patients with RRMM
Several phase 1/2 studies of carfilzomib generated efficacy and safety data supporting progression into phase 3 trials in patients with MM. 64 above AEs were reported in 62% of patients treated with carfilzomib at the MTD. Among this group, the most common AEs reported at grade 3 or above were fatigue (11%), hypertension (7%), pneumonia, acute kidney injury, thrombocytopenia, and anemia (all 6%). 71 The ongoing ARROW phase 3 trial will add to these data by comparing the safety and efficacy of once-weekly carfilzomib 70 mg/m 2 with twice-weekly dosing at 27 mg/m 2 in patients with RRMM. 72 Evidence supporting the approval of carfilzomib was provided by the ASPIRE phase 3 trial, which produced remarkable results in the relapsed setting (Table 2) . 73 The addition of twice-weekly carfil- 
| Clinical trials in patients with newly diagnosed MM
Early-phase trial data suggest that carfilzomib may also benefit newly diagnosed patients with MM. In a phase 1/2 study, the combination of twice-weekly carfilzomib with melphalan and prednisone produced an ORR of 90% in patients with newly diagnosed MM who were at least 66 years of age. 64 The combination of carfilzomib, lenalidomide, and low-dose dexamethasone was also effective and well tolerated in patients with newly diagnosed MM in a phase 1/2 trial.
After an extended follow-up (median 25 months), a nCR or better was reported in 72% of patients, and the estimated 2-year PFS and OS rates were 94% and 98%, respectively. and 0%, respectively, for cyclophosphamide-treated patients). Stem cell mobilization was higher in the cyclophosphamide arm compared with the lenalidomide arm (99% vs 95%; P = .44); however, the rate of VGPR or better was higher in the lenalidomide arm than the cyclophosphamide arm (74% vs 61%; P = .05).
77
A phase 1b single-arm trial assessed the safety and efficacy of twice-weekly carfilzomib (in combination with cyclophosphamide and dexamethasone) in patients with symptomatic myeloma for whom SCT was not suitable (CHAMPION-2) . The ORR was 88%, and the median time to response was 1 month. No dose-limiting toxicities were identified, and the most common AEs at grade 3 or above were anemia (25%), hypokalemia (19%), and neutropenia (19%). 78 The safety and efficacy of once-weekly carfilzomib (in combination with cyclophosphamide and dexamethasone) in elderly patients with newly diagnosed MM were investigated in a phase 1/2 study.
The MTD for carfilzomib was established as 70 mg/m 2 . After 4 induction cycles, 83% of patients achieved a PR or better. Overall, the regimen was well tolerated; the most common treatment-related grade 3 or 4 AEs were neutropenia, anemia, and acute pulmonary edema. 79 
| IX A ZOMIB
Ixazomib is a second-generation, reversible proteasome inhibitor with a boronic acid active moiety (Figure 1 ) that has been approved in the United States and in Europe in combination with lenalidomide and dexamethasone for the treatment of adult patients with MM who have received at least 1 previous therapy. 19, 20 This agent has oral bioavailability, which means that, unlike bortezomib and carfilzomib, it can be administered in capsule form. Ixazomib preferentially binds the β5-subunit of the constitutive proteasome with a level of selectivity similar to that of bortezomib, but can inhibit other proteolytic sites within the proteasome at high concentrations. (Table 2) . 81 The interim analysis also showed that the ORRs, CR rates, and rates of VGPR or better were all significantly higher in the ixazomib group than in the control group. 81 In the interim subgroup analysis of the TOURMALINE-MM1 trial, the median PFS for patients with high-risk cytogenetics was 21.4 months in the ixazomib group and 9.7 months in the control group (HR, 0.54; P = .002).
81
In the TOURMALINE-MM1 study, 17% of patients in the ixazomib group and 14% of patients in the control group discontinued treatment owing to AEs. The most common grade 3 or 4 AEs in the ixazomib arm and the control arm were neutropenia (22% and 25%, respectively), thrombocytopenia (19% and 9%), and anemia (9% and 13%). AEs of grade 3 or above that were more common in the ixazomib arm than in the control arm included diarrhea (6% vs 3%), rash (5% vs 2%), and arrhythmia (6% vs 3%). Of note, rates of peripheral neuropathy in the ixazomib group were similar to those recorded in the control group (27% vs 22% at all grades, and 2% vs 2% at grade 3 or 4). 81 Ongoing phase 3 clinical trials are assessing the use of ixazomib in patients with newly diagnosed MM and in those with MM who have received SCT.
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| HE AD -TO -HE AD TRIAL S COMPARING PROTE A SOME INHIB ITOR S
Studies directly comparing drugs from the same class for the treatment of MM are rare. The phase 3 ENDEAVOR trial, however, compared carfilzomib with intravenous or subcutaneous bortezomib in patients with RRMM. 85 Patients with relapsed MM who had received from 1 to 3 previous lines of therapy were randomized to receive either twice-weekly carfilzomib (starting dose: 20 mg/m 2 ; target dose: 56 mg/m 2 ) plus dexamethasone or twiceweekly bortezomib (1.3 mg/m 2 ) plus dexamethasone ( Table 2 ).
This study met its primary endpoint: Treatment with carfilzomib and dexamethasone resulted in a significantly longer PFS than treatment with bortezomib and dexamethasone (18.7 months vs 9.4 months; HR, 0.53; P < .0001) at a preplanned interim analysis.
A significant PFS benefit was observed in patients receiving carfilzomib, both with and without previous bortezomib treatment.
The ORR was significantly higher in the carfilzomib group than in the bortezomib group (77% vs 63%; P < .0001) as was the proportion of patients achieving CR or better (13% vs 6%; P = .001).
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The most common grade 3 or higher AEs in the carfilzomib and bortezomib groups were anemia (14% and 10%, respectively), hypertension (9% and 3%), thrombocytopenia (8% and 9%), and pneumonia (7% and 8%). 85 Dose reductions because of AEs were more common in the bortezomib group than in the carfilzomib group (48% vs 23%), as were discontinuations due to AEs (16% vs 14%). The proportion of patients with peripheral neuropathy (grade 2 or above) was significantly higher in the bortezomib arm than the carfilzomib arm (32% vs 6%; P < .0001), and this trend was irrespective of peripheral neuropathy status at baseline.
Among patients receiving bortezomib, peripheral neuropathy was the most common cause of dose reductions (62%) and discontinuations (2%). 85 Toxicities at grade 3 or above that were more common in the bortezomib arm than in the carfilzomib arm included diarrhea (7% vs 3%) and fatigue (7% vs 5%). By contrast, toxicities at grade 3 or above that were observed more frequently in the carfilzomib arm than in the bortezomib arm included anemia (14% vs 10%), cardiac failure (5% vs 2%), dyspnea (5% vs 2%), and hypertension (9% vs 3%). Discontinuations related to these AEs, however, were few. Notably, the incidence of grade 2 or above peripheral neuropathy was lower in the carfilzomib group than in the bortezomib group (2.5% and 35.1%, respectively).
90,91
The ongoing ENDURANCE phase 3 trial is comparing bortezomib with carfilzomib, when combined with lenalidomide and lowdose dexamethasone in patients with newly diagnosed symptomatic MM. 92 The findings from this study will inform the discussion on the relative effectiveness of bortezomib and carfilzomib in the first-line setting in patients with MM.
| RE S IS TAN CE TO PROTE A SOME INHIB ITOR S
Acquired resistance to proteasome inhibition represents a considerable clinical challenge in the treatment of patients with MM. 80 It is important to understand the molecular basis of resistance in order to develop strategies to overcome this issue and to maximize the benefit that patients with MM derive from treatment with proteasome inhibitors. Our current understanding of adaptive proteasome inhibitor resistance is incomplete. Mutations in the PSMB5 gene, which codes for the proteasome β5-subunit protein, by diminishing proteasome inhibitor binding, may lead to the development of resistance 93 ; however, this has not been corroborated. showed that the protein most upregulated in carfilzomib-resistant cells was ABCB1, an efflux pump (also known as P-glycoprotein), but upregulation of ABCB1 was not observed in bortezomib-resistant cells. 63 Furthermore, a recent in vitro study found that the protease inhibitors nelfinavir and lopinavir-potent functional modulators of ABCB1-mediated drug export-can restore carfilzomib activity at clinically tolerable levels. 99 An improved understanding of the -mechanisms underlying proteasome inhibitor resistance is required to inform the development of effective strategies against this emerging challenge in MM. The differing safety profiles of carfilzomib and bortezomib and the different label specifications indicate the potential benefit of longer duration of treatment with carfilzomib. Bortezomib is currently approved for a maximum of 8 treatment cycles in the second-line setting, whereas carfilzomib (with dexamethasone) and ixazomib (with lenalidomide and dexamethasone) are approved for use until disease progression or unacceptable toxicity occurs. 7, 18, 20 Phase 3 data on the benefit-risk profile of bortezomib and low-dose dexamethasone in patients with RRMM are available only from clinical trials in which this combination was used as an active control. In the phase 3 CASTOR trial, patients in the subcutaneous bortezomib plus low-dose dexamethasone arm received a maximum of 8 cycles of treatment. The PFS for this group of patients was 7.2 months, and the incidence of treatment-emergent peripheral neuropathy, anemia, and thrombocytopenia (at any grade) was 38%, 31%, and 44%, respectively. Despite this, only 9 percent of patients discontinued bortezomib-low-dose dexamethasone due to treatmentrelated AEs. . 38 The median PFS in this group of patients was 8.1 months and commonly reported AEs (at any grade) included peripheral neuropathy (67%), anemia (52%), and thrombocytopenia (84%); 12% of patients discontinued treatment owing to treatment-related AEs. 38 In the ENDEAVOR trial patients were treated with either carfilzomib or bortezomib combined with low-dose dexamethasone until disease progression or unacceptable toxic effects. The median treatment duration in the bortezomib arm was 26.8 weeks (IQR, 15.0-42.0 weeks), and the median PFS was 9.4 months. The incidence of peripheral neuropathy, anemia, and thrombocytopenia (at any grade) was 32%, 27%, and 17%, respectively. Adverse events leading to discontinuation in the bortezomib arm were reported in 16% of patients. 85 More data are needed to clarify whether there is any benefit associated with extending treatment with bortezomib and low-dose dexamethasone beyond the 8 cycles for which this combination is approved currently.
| US ING PROTE A SOME INHIB ITOR S IN PATIENTS WITH RRMM
With bortezomib widely used as a first-line treatment, the choice of second-line regimen is likely to be lenalidomide or carfilzomib based; however, positive findings from the POLLUX phase 3 study suggest that daratumumab-lenalidomide-low-dose dexamethasone is an additional option for patients with RRMM who have received bortezomib in previous treatment lines, if a switch in drug class is desired. 103 The addition of daratumumab to carfilzomib-low-dose dexamethasone in patients with RRMM is being evaluated in phase 3 trials. 104 Although distinct trial populations make direct comparisons impossible, it is clear that the introduction of proteasome inhibitors, either alone or in combination with immunomodulatory drugs, has resulted in unprecedented increases in PFS in patients with RRMM. New regimens will now be evaluated against triplet regimens offering PFS of over 
| PROTE A SOME INHIB ITOR S IN DE VELOPMENT
Oprozomib, an orally administered epoxyketone-based irreversible inhibitor of the proteasome β5-subunit, 105 has shown promise in phase 1 studies. 21, 22 Marizomib, an intravenously administered salinosporamide-based agent that has also entered phase 1 clinical trials, irreversibly inhibits all 3 proteolytic subunits. 106 Therapies that target the β2-subunit have already demonstrated activity in MM cell lines in vitro.
| CON CLUS IONS
The Carfilzomib was associated with longer PFS than bortezomib in a head-to-head phase 3 study in patients with RRMM, and other headto-head trials between these proteasome inhibitors are ongoing. 85, 92 Modification of the carfilzomib dosing frequency from twice-weekly to once-weekly is currently being examined and may be achieved without loss of efficacy. 71, 72 In the past, treatment-free intervals were an important goal of MM therapy. Now, evidence is emerging for the benefit of extended therapy, as newer and more tolerable regimens become available.
Earlier use of combinations of agents with different mechanisms of action such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies could potentially provide a functional curative option for some patients with MM.
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